Spike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection
Open Access
- 15 November 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10225
Abstract
Severe acute respiratory syndrome 2 (SARS-CoV-2), the single-stranded RNA virus responsible for Coronavirus Disease 2019 (COVID-19), continues to circulate globally, with the emergence of antigenically distinct variants posing ongoing challenges to vaccine effectiveness. In particular, Omicron subvariants harbor numerous mutations in the receptor-binding domain (RBD), which contribute to immune evasion and reduced susceptibility to neutralization by antibodies. Previous COVID-19 mRNA vaccines encoding the spike (S) protein of the ancestral SARS-CoV-2 or early variants of concern have demonstrated limited efficacy against Omicron subvariants, underscoring the need for next-generation vaccines capable of eliciting broad-spectrum neutralizing antibodies against Omicron and providing cross-protection against antigenically distinct variants. In this study, we designed an mRNA vaccine encoding a conserved Omicron-S backbone incorporating the JN.1 RBD (S-JN1-RBD), formulated the mRNA with lipid nanoparticles (LNPs), and evaluated its neutralizing activity and protective efficacy. This mRNA-LNP formulation exhibited an appropriate particle size and high thermal stability. It elicited cross-reactive antibodies against S proteins harboring diverse Omicron-RBDs, resulting in broad neutralizing activity against multiple pseudotyped and authentic SARS-CoV-2 Omicron subvariants. Importantly, this vaccine conferred cross-protection against challenge with the heterologous, antigenically divergent XBB.1.5 Omicron subvariant in human angiotensin-converting enzyme 2-transgenic mice. Furthermore, passive transfer of immune sera protected mice against infection with the Omicron-KP.3 subvariant, providing additional evidence of the vaccine’s broad protective potential. These findings underscore the potential of the designed mRNA immunogen to elicit broad-spectrum neutralizing antibody responses and to confer cross-protection against diverse and emerging SARS-CoV-2 subvariants.Keywords
This publication has 66 references indexed in Scilit:
- mRNA vaccines for viral diseases: mechanism, advances, and future perspectiveMolecular Biology Reports, 2026
- The Emergence and Characterization of SARS-CoV-2 Variant XFG (“Stratus”): Comparative Virological, Epidemiological, and Public-Health PerspectivesJournal of Epidemiology and Global Health, 2026
- Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipientsAntiviral Research, 2025
- Advances in the design and delivery of RNA vaccines for infectious diseasesAdvanced Drug Delivery Reviews, 2024
- The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategiesMedcomm, 2024
- mRNA vaccine in cancer therapy: Current advance and future outlookClinical and Translational Medicine, 2023
- mRNA vaccines: Past, present, futureAsian Journal of Pharmaceutical Sciences, 2022
- The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibitionFEBS Open Bio, 2022
- BNT162b2 mRNA COVID-19 Vaccine: First ApprovalDrugs, 2021
- The flexibility of ACE2 in the context of SARS-CoV-2 infectionBiophysical Journal, 2021